Faculty profile

Denis Leclerc

ResearcherMicrobiologie et d'infectiologieUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Denis Leclerc

Researcher

Microbiologie et d'infectiologie

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
5 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 16 research grants (8 CIHR, 8 NSERC), most recently in 2024.
Supervised 1 trainee who won CIHR awards, most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Vaccine Platform Innate Immunity Sortase Vaccine Nanoparticles 2019-Ncov Broad Protection Coronavirus

Latest papers

Engineering a Modular PapMV Nanoparticle Vaccine: Comparative Efficacy of a Covalent and a Non-Covalent N-Antigen Vaccine Against Emerging SARS-CoV-2 Variants.
Vaccines · 2026 · senior author
PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines.
Nanomedicine : nanotechnology, biology, and medicine · 2026 · senior author
Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis.
Oncoimmunology · 2024

All 44 publications

Latest funding

The Pursuit of a SARS-CoV-2 Vaccine: Aiming for Broad Protection
CIHR · 2024 · Nominated PI
$300,000
Cryo-TEM infrastructure for the visualisation of nanoparticles, exosomes, and virus-like particles
NSERC · 2023 · Co-investigator
$150,000
Preclinical proof of concept studies of a new generation of TLR7/8 agonist used in prevention against respiratory viruses and in immunotherapy against lung cancer.
CIHR · 2022 · Nominated PI
$100,000

All 25 grants and awards

44 publications.

Engineering a Modular PapMV Nanoparticle Vaccine: Comparative Efficacy of a Covalent and a Non-Covalent N-Antigen Vaccine Against Emerging SARS-CoV-2 Variants.

Blanchette LJ, Bolduc M, Woldemariam T, Yousefi M, Rabezanahary H, Olivera-Ugarte SM, Garneau C, Angers M, Shi R, Flamand L, Baz M, Vidal S, Falzarano D, Lemay JF, Leclerc D

Vaccines2026Senior author

DOI: 10.3390/vaccines14040349 PMID: 42042825

PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines.

Bolduc M, Saint-Louis P, Carignan D, Garneau C, Breton Y, Pelletier M, Rancourt A, Satoh MS, Sato S, Gilbert M, Rabezanahary H, Baz M, Dubuc I, Flamand L, Leclerc D

Nanomedicine : nanotechnology, biology, and medicine2026Senior author

DOI: 10.1016/j.nano.2025.102887 PMID: 41354257

Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis.

Bourguignon L, Hétu-Arbour R, Charpentier T, Bolduc M, Leclerc D, Heinonen KM, Lamarre A

Oncoimmunology2024

DOI: 10.1080/2162402x.2024.2429846 PMID: 39552216

A rapid procedure to generate stably transfected HEK293 suspension cells for recombinant protein manufacturing: Yield improvements, bioreactor production and downstream processing.

Dash S, Farnós O, Yang Z, Sudalaiyadum Perumal A, Chaves Fulber JP, Venereo-Sánchez A, Leclerc D, Kamen AA

Protein expression and purification2023

DOI: 10.1016/j.pep.2023.106295 PMID: 37201590

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.

Olivera-Ugarte SM, Bolduc M, Laliberté-Gagné MÈ, Blanchette LJ, Garneau C, Fillion M, Savard P, Dubuc I, Flamand L, Farnòs O, Xu X, Kamen A, Gilbert M, Rabezanahary H, Scarrone M, Couture C, Baz M, Leclerc D

Nanomedicine : nanotechnology, biology, and medicine2022Senior author

DOI: 10.1016/j.nano.2022.102584 PMID: 35850421

MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy.

Possamaï D, Hanafi LA, Bellemare-Pelletier A, Hamelin K, Thébault P, Hébert MJ, Gagnon É, Leclerc D, Lapointe R

PloS one2021

DOI: 10.1371/journal.pone.0261987 PMID: 34972158

Modulation of Antigen Display on PapMV Nanoparticles Influences Its Immunogenicity.

Laliberté-Gagné ME, Bolduc M, Garneau C, Olivera-Ugarte SM, Savard P, Leclerc D

Vaccines2021Senior author

DOI: 10.3390/vaccines9010033 PMID: 33435570

Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation.

Farnós O, Venereo-Sánchez A, Xu X, Chan C, Dash S, Chaabane H, Sauvageau J, Brahimi F, Saragovi U, Leclerc D, Kamen AA

Vaccines2020

DOI: 10.3390/vaccines8040654 PMID: 33158147

A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of Age.

Langley J, Pastural E, Halperin S, McNeil S, ElSherif M, MacKinnon-Cameron D, Ye L, Grange C, Thibodeau V, Cailhier JF, Lapointe R, McElhaney J, Martin L, Bolduc M, Laliberté-Gagné ME, Leclerc D, Savard P

Vaccines2020

DOI: 10.3390/vaccines8030393 PMID: 32698532

Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform.

Laliberté-Gagné MÈ, Bolduc M, Thérien A, Garneau C, Casault P, Savard P, Estaquier J, Leclerc D

Vaccines2019Senior author

DOI: 10.3390/vaccines7020049 PMID: 31212772

The Pursuit of a SARS-CoV-2 Vaccine: Aiming for Broad Protection

Nominated PICIHR2024Cat: Develop./validation of new biomedical techniques/technolo.-Infec.and Immun.

Principal investigators: Leclerc, Denis

Keywords: Flexuous Rod Shape Nanoparticle; Humoral And T Cell Immune Response; Sars-C0v-2 Kp.3 Variant; Sars-Cov-2 Nucleocapsid; Sars-Cov-2 Receptor Binding Domain; Sars-Cov-2 Vaccine; Sorties Mediated Coupling; Toll Like Receptor 7/8 Agonist; Vaccine Platform; Vaccine With Broad Protection

$300,000

Cryo-TEM infrastructure for the visualisation of nanoparticles, exosomes, and virus-like particles

Co-investigatorNSERC2023Research Tools and Instruments

Principal investigators: Fortin, Marc-André

$150,000

Preclinical proof of concept studies of a new generation of TLR7/8 agonist used in prevention against respiratory viruses and in immunotherapy against lung cancer.

Nominated PICIHR2022Project Grant - PA: Pandemic Preparedness and Health Emergencies Research

Principal investigators: Leclerc, Denis

Keywords: Innate Immunity; Lung Cancers; Nanoparticles; Non Small Cell Lung Cancer (Nsclc); Nsclc Immunotherapy; Prevention Implantation Cancer Cells; Prevention Respiratory Viral Infections; Respiratory Viruses; Sars-Cov-2; Tlr 7/8 Agonist

$100,000

COVID-19 Variant Supplement - Development of a nanoparticle-based vaccine candidate to the SARS-CoV-2

Nominated PICIHR2021Operating Grant: SARS-CoV-2 variants supplement stream 1

Principal investigators: Leclerc, Denis

Keywords: 2019-Ncov; Broad Protection; Coronavirus; Ctl Response; Nanoparticle; Nucleoprotein; Peptide Based Vaccine; Sortase; Vaccine; Vaccine Platform

$50,000

Developing synthetic S100A9-based molecules for differentiation therapy of human acute myeloid leukemia

Co-investigatorCIHR2021Project Grant

Principal investigators: Tessier, Philippe A

Keywords: Animal Models; Drug Development; Leukemia; Myeloid Cells; Protein Structure; S100 Proteins

$753,525

Coronavirus Variants Rapid Response Network: CoVaRR-Net

Co-investigatorCIHR2021Operating Grant: CIHR Network for Emerging COVID-19 Variants Research

Principal investigators: Langlois, Marc-Andre; Brouwers, Melissa C; Flamand, Louis; Gingras, Anne-Claude; Gommerman, Jennifer L; Muhajarine, Nazeem; Ragoussis, Ioannis; Shapiro, Jesse

Keywords: Covarr-Net; Covid-19; Rapid-Response; Sars-Cov-2; Variants Of Concern

$9,000,000

Coronavirus Variants Rapid Response Network: CoVaRR-Net - Extension

Co-investigatorCIHR2021Op. Gr.: Coronavirus Variants Rapid Response Network (CoVaRR-Net) Extension

Principal investigators: Langlois, Marc-Andre; Abraham, Ninan; Behr, Marcel A; Brouwers, Melissa C; Crawley, Angela M; Flamand, Louis; Gingras, Anne-Claude; Gommerman, Jennifer L; Grimshaw, Jeremy M; Hsu, Amy T; Huyser, Kimberly R; Manuel, Douglas G; Muhajarine, Nazeem; Ragoussis, Ioannis; Rasmussen, Angela; Shapiro, Jesse

Keywords: Covarr-Net; Covid-19; Rapid-Response; Sars-Cov-2; Variants Of Concern

$9,000,000

Development of a nanoparticle-based vaccine candidate to the SARS-CoV-2

Nominated PICIHR2020Operating Grant: COVID-19 - Vaccines

Principal investigators: Leclerc, Denis

Keywords: 2019-Ncov; Broad Protection; Coronavirus; Ctl Response; Nanoparticle; Nucleoprotein; Peptide Based Vaccine; Sortase; Vaccine; Vaccine Platform

$717,645

Adjuvantization of SIV antigens using a novel toll like receptor 7 (TLR7) agonist: A proof of concept in non human primate.

Nominated PICIHR2017Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research

Principal investigators: Leclerc, Denis

Keywords: Dendritic Cells; Hiv; Innate Immunity; Macaque; Nanoparticles; Papmv; Siv; Sortase; Tlr7; Vaccine

$250,000

Structure and Engineering of papaya mosaic virus nanoparticles

Principal investigatorNSERC2016Discovery Grants Program - Individual

Principal investigators: Leclerc, Denis

$228,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Denis Leclerc

Research

Latest papers

Latest funding

Engineering a Modular PapMV Nanoparticle Vaccine: Comparative Efficacy of a Covalent and a Non-Covalent N-Antigen Vaccine Against Emerging SARS-CoV-2 Variants.

PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines.

Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis.

A rapid procedure to generate stably transfected HEK293 suspension cells for recombinant protein manufacturing: Yield improvements, bioreactor production and downstream processing.

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.

MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy.

Modulation of Antigen Display on PapMV Nanoparticles Influences Its Immunogenicity.

Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation.

A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of Age.

Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform.

The Pursuit of a SARS-CoV-2 Vaccine: Aiming for Broad Protection

Cryo-TEM infrastructure for the visualisation of nanoparticles, exosomes, and virus-like particles

Preclinical proof of concept studies of a new generation of TLR7/8 agonist used in prevention against respiratory viruses and in immunotherapy against lung cancer.

COVID-19 Variant Supplement - Development of a nanoparticle-based vaccine candidate to the SARS-CoV-2

Developing synthetic S100A9-based molecules for differentiation therapy of human acute myeloid leukemia

Coronavirus Variants Rapid Response Network: CoVaRR-Net

Coronavirus Variants Rapid Response Network: CoVaRR-Net - Extension

Development of a nanoparticle-based vaccine candidate to the SARS-CoV-2

Adjuvantization of SIV antigens using a novel toll like receptor 7 (TLR7) agonist: A proof of concept in non human primate.

Structure and Engineering of papaya mosaic virus nanoparticles

Frequent collaborators

Alain Lamarre

Louis Flamand

Guy Boivin

Silvia Vidal

Philippe Tessier

Martin Pelletier

Réjean Lapointe

Amine Kamen

Darryl Falzarano

Michel Duval

Sachiko Sato

Scott Halperin

Shelly McNeil

Joanne Langley